Company: VEEV
Filing Date: 2025-06-02
Form Type: 10-Q
Source: 0001393052-25-000042
Chunk: 146

Company: VEEVA SYSTEMS INC
Filing Date: 2025-06-02
Form: 10-Q
Item: Part I, Item 1
Chunk 146
---
 on cash, cash equivalents, and restricted cash766 (1,257)Net change in cash, cash equivalents, and restricted cash846,197 493,709 Cash, cash equivalents, and restricted cash at beginning of period1,120,963 706,670 Cash, cash equivalents, and restricted cash at end of period$1,967,160 $1,200,379 Cash, cash equivalents, and restricted cash at end of period:Cash and cash equivalents$1,964,982 $1,197,196 Restricted cash included in other long-term assets2,178 3,183 Total cash, cash equivalents, and restricted cash at end of period$1,967,160 $1,200,379 Supplemental disclosures of other cash flow information:Cash paid for income taxes, net of refunds$13,850 $4,229 Excess tax benefits from employee stock plans$2,579 $3,121 

See Notes to Condensed Consolidated Financial Statements.

Veeva Systems Inc. | Form 10-Q7

Table of Contents

VEEVA SYSTEMS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Summary of Business and Significant Accounting Policies 

Description of BusinessVeeva is the leading provider of industry cloud solutions for the global life sciences industry. Our offerings span cloud software, data, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) through commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, regulatory, quality, and safety functions help life sciences companies streamline their end-to-end product development and quality and manufacturing processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. Our solutions for clinical research sites enable regulatory documents and trial information to be managed in a modern cloud solution that is intended to accelerate the clinical research process for the life sciences industry overall. Our fiscal year end is January 31.

Principles of Consolidation and Basis of PresentationThese unaudited condensed consolidated financial statements have been prepared in accordance with generally